Rubicon Research Ltd Q1 FY27 Earnings Call: Revenue Surges 52% YoY, Acquires US Site for $2.9 Mn

Rubicon Research Ltd held its Q1 FY27 earnings call on August 14, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Revenue surges 52% YoY; PAT nearly doubles

• Revenue from operations of Rs.5,343 Mn (Rs.534 Cr) — up 51–52% YoY in Q1 FY2026-2027, driven by broad-based growth across the portfolio and the Arena acquisition closed in April.
• Operating EBITDA of Rs.1,291 Mn (Rs.131 Cr) — up 65% YoY; margin expanded to 24.2% from 22.4% in Q1 FY2025-2026, supported by gross margin improvement and operating leverage.
• PAT of Rs.848 Mn (Rs.86 Cr) — grew 96% YoY, including a one-off insurance claim in other income; EPS for the quarter stood at Rs.5.08.
• USD revenue of $55 Mn — up 32% YoY from $42 Mn in Q1 FY2025-2026; sequential decline reflected tactical measures to shed lower-margin business.
• Gross margin rose 140 bps QoQ to 67.7% — achieved despite higher input and freight costs, aided by a shift toward specialty products and reduced reliance on low-margin contract manufacturing.
• Pre-R&D EBITDA margin improved to 35% — from 32.5% YoY; pre-R&D EBITDA reached Rs.1,871 Mn in Q1 FY2026-2027.

Specialty shift and deliberate pruning lift gross profit profile

• Specialty portfolio contributed 36% of gross profit — management walked away from lower-margin US business in Q1 FY2026-2027, driving the share of specialty in gross profit higher; US revenue grew 50% YoY despite the pruning.
• Indian revenue grew 9.7% in Q1 FY2026-2027 — domestic performance remained steady, though significantly outpaced by the US-led export growth.
• Top 5 products contributed 39% of Q1 FY2026-2027 revenue — top 10 contributed 55%, a range that management described as "range-bound" over recent quarters, indicating broad-based portfolio diversification.
• Product approval commercialization rate of 88% — some products from the pipeline are expected to be commercialized in the next two quarters; management continues to see growth even from products launched 8–10 years ago.
• Tactical measures included shedding lower-margin contract manufacturing — management confirmed that reliance on outsourced manufacturing has increased over recent quarters, impacting gross margins, and that the company is actively addressing this through the shift toward own manufacturing.
• Transfer pricing compliance confirmed — management stated there has been "no sharp movement" in the transfer-pricing mechanism, attributing input cost movements to the mix of own manufacturing, outsourced manufacturing, and traded goods.

US site acquired via bankruptcy; multi-site India network expands

• Acquired a US manufacturing site in East Brunswick, New Jersey for $2.9 Mn — via a court-supervised bankruptcy process in Q1 FY2026-2027; the facility has a 10-year USFDA track record and an FDA inspection in May 2026 concluded with a VAI classification. Management expects commercialization in calendar 2027 for specialty/high-value products and US government customers.
• Arena Life Sciences contributed Rs.12 Cr to Q1 FY2026-2027 revenue — EBITDA contribution described as "not material" and "flattish"; after adjusting for Arena, base business EBITDA margins in the quarter were slightly higher than the reported consolidated level.
• Pithampur site carries Rs.1,500 Mn in pre-revenue capex — only 6 of 30 acres are currently utilized; management expects a gradual ramp-up over 9–12 months through FY2027-2028, with commercialization starting in Q1 FY2027-2028. The site received an FDA 483 with two procedural observations; a response was filed and FDA approval on a regulatory filing was received post-inspection.
• Multi-site manufacturing strategy detailed — Ambernath (core oral solids and nasal sprays), Satara (liquids, nasal backup), Indore (hormones, steroids, high-potent, large capacities), the Alkem site (very large batch sizes, continuous processing), and the CAS site (niche dosage forms). Management stated that capex will always lag sales and is driven by available revenue capability from the portfolio.
• US acquisition expected to be margin accretive — management stated the New Jersey site "will not dilute gross margins" and is strategic for entering the government/VA business, proximity to customers, and risk diversification across India and US supply chains.

R&D spend guided at Rs.500 Cr over nine quarters; productivity at 5.5x

• R&D expense of Rs.580 Mn (10.9% of revenue) in Q1 FY2026-2027 — versus Rs.355 Mn in Q1 FY2025-2026; management guided that R&D will remain at 10–11% of sales (period unspecified), which it described as "industry-leading."
• R&D productivity of 5.5x — calculated as incremental revenue vs. lagged R&D spend for FY2024-2025 vs. FY2026-2027 (annualised based on Q1 FY2026-2027 revenue), excluding Arena Life Sciences. Management expects this multiple to expand during the year.
• Rs.500 Cr of R&D spend guided over nine quarters — covering FY2026-2027, FY2027-2028, and Q1 FY2028-2029. As of Q1 FY2026-2027, Rs.251 Cr has been completed over five quarters; current quarterly run rate is ~Rs.60 Cr. Management expects to meet the guidance comfortably by Q1 FY2028-2029.
• Historical R&D spend normalized from 39.5% of revenue in FY2021-2022 — reflecting the transition from a development-stage company to a commercial-stage enterprise with operating leverage.
• Six IPO-era products tracked — four saw both market share and rank increase; one saw rank increase despite marginal share decline; one maintained rank despite marginal share decline. Management cited market execution as a competitive moat.
• At the time of filing the RHP, 63 products were in advanced stages of development — management does not provide further pipeline details for competitive reasons; the number of products under FDA review (24 in Q4 FY2025-2026) will now be disclosed only once a year.

CFO transitions to CCO; working capital improves to 114 days

• CFO Nitin Jajodia transitioning to Chief Commercial Officer (CCO) — Rohit will join as CFO designate and assume the role as Nitin transitions; the move is part of building management bandwidth and succession planning as Rubicon expands into new business areas. Nitin joined in 2021 when revenue was ~Rs.400 Cr; for FY2025-2026, revenue stood at Rs.1,700 Cr.
• Net working capital days improved to 114 days — as of 30 June 2026, down from 126 days as of 31 March 2026; management reiterated a working capital guidance of 125–130 days (period unspecified).
• Operating cash flow of Rs.285 Mn in Q1 FY2026-2027 — before working capital change, cash flow was Rs.1,390 Mn; the lower net figure was due to delayed GST refunds, which management expects to normalize in Q2 FY2026-2027.
• ROAC of 36% — achieved despite significant pre-revenue capital deployed at Pithampur and the US acquisition, indicating strong returns on the active capital base.
• AI and automation adopted selectively — with a focus on regulatory compliance and robust validation in pharmaceutical settings; no quantitative impact or revenue contribution was disclosed.
• Investing cash outflows driven by Arena acquisition and capex — management confirmed the company follows a patient, long-term M&A strategy, with the adjacent location of the US site cited as a key advantage.

FY27 EBITDA guidance revised up to 23%; Pithampur ramp from Q1 FY28

• FY2026-2027 EBITDA guidance revised upwards to 23% — from the prior range of 22–23%; the revision incorporates the impact of ESOP cost, Arena-related expenses, and pre-revenue costs for new facilities. Consolidated EBITDA guidance for FY2026-2027 implies near-term margin dilution from the Arena build-out.
• Q2 FY2026-2027 tracking strong for sequential USD revenue growth — management indicated that the Q1 sequential decline in USD revenue was tactical and that Q2 is trending positively.
• Pithampur commercialization starts in Q1 FY2027-2028 — with a gradual ramp-up over 9–12 months through FY2027-2028; the site has significant headroom with only 6 of 30 acres utilized.
• Arena phased strategy outlined — FY2026-2027 focuses on identifying and fixing growth levers; the next phase aims to beat IPM growth; profitability is a later-stage priority. Near-term margins will reflect this investment phase.
• US site (New Jersey) commercialization in calendar 2027 — expected to be margin accretive and serve specialty/high-value products and US government customers; management cited risk diversification across India and US supply chains as a strategic benefit.
• Management does not provide forward pipeline details — for competitive reasons, and the number of products under FDA review will be disclosed annually rather than quarterly. No specific revenue or margin guidance was provided beyond FY2026-2027.
• Next earnings call scheduled for Q2 FY 2026-2027 — management closed with no additional financial figures or guidance beyond what was discussed.